Inhibrx End Period Cash Flow from 2010 to 2025

INBX Stock  USD 13.49  0.05  0.37%   
Inhibrx End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2025. During the period from 2010 to 2025, Inhibrx End Period Cash Flow regression line of annual values had r-squared of  0.70 and arithmetic mean of  102,140,489. View All Fundamentals
 
End Period Cash Flow  
First Reported
2018-03-31
Previous Quarter
226.9 M
Current Value
196.3 M
Quarterly Volatility
101.3 M
 
Covid
Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx's main balance sheet or income statement drivers, such as Interest Expense of 38.4 M, Minority Interest of 0.0 or Tax Provision of 2.6 K, as well as many indicators such as Price To Sales Ratio of 940, Dividend Yield of 0.0021 or PTB Ratio of 38.9. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules.
  
Check out the analysis of Inhibrx Correlation against competitors.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.

Latest Inhibrx's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Inhibrx over the last few years. It is Inhibrx's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Inhibrx End Period Cash Flow Regression Statistics

Arithmetic Mean102,140,489
Geometric Mean40,767,616
Coefficient Of Variation123.07
Mean Deviation106,764,612
Median20,025,000
Standard Deviation125,702,390
Sample Variance15801.1T
Range333.5M
R-Value0.84
Mean Square Error5057.4T
R-Squared0.70
Significance0.000052
Slope22,110,171
Total Sum of Squares237016.4T

Inhibrx End Period Cash Flow History

2025335.6 M
2024319.6 M
2023277.9 M
2022273.9 M
2021131.3 M
2020128.7 M
201911.5 M

About Inhibrx Financial Statements

Inhibrx investors use historical fundamental indicators, such as Inhibrx's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow319.6 M335.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.